Spruce Biosciences (SPRB) has a dividend yield of 0.00%, as the company does not pay regular dividends to its common stockholders. Being a clinical-stage biopharmaceutical enterprise, all incoming capital resources and cash reserves are strictly retained and reinvested into ongoing research, drug development pipelines, and clinical trial operations.